Other

2017 Subject Index

Turk J Pharm Sci 2017;14(3):0-0

2017 Subject Index

1H-NMR................................................................................. 49

2,3-dihydro-1,4-benzodioxin-6-amine.................................... 49

Acetohydrazide...................................................................... 285

Acinetobacter.......................................................................... 13

Activity of melatonin................................................................ 75

Adenosine A2B receptors........................................................ 19

Agmatine............................................................................... 127

AMPK................................................................................... 207

Androgen receptor................................................................ 274

Anti-inflammatory................................................................. 231

Anti-inflammatory activity..................................................... 108

Antibacterial activity.............................................................. 157

Antibacterial potential............................................................. 49

Antineoplastic........................................................................ 304

Antioxidant............................................................................ 311

Antioxidant activity................................................................ 174

Antiproliferative...................................................................... 29

Antitubercular activity........................................................... 157

Antiviral activity.................................................................... 157

AP-PCR................................................................................... 13

Apoptosis....................................................................... 169,222

Artemisia absinthium............................................................ 222

Artificial neural networks...................................................... 213

Arylidenehydrazide............................................................... 157

Asteraceae............................................................................. 290

AUC...................................................................................... 108

Benzimidazole....................................................................... 285

Biodegradable......................................................................... 34

Biomechanic............................................................................ 65

cAMP...................................................................................... 19

Cancer cells.......................................................................... 222

Carbonic anhydrase................................................................. 9

Carvacrol................................................................................ 29

Cell death.............................................................................. 169

Characterization.............................................................. 34,280

Checkerboard......................................................................... 13

Chemotherapy....................................................................... 304

CHO cells............................................................................. 185

Chrysophthalmum montanum.............................................. 290

Clinical trials.......................................................................... 84

Clonazepam.......................................................................... 251

Clove oil................................................................................ 201

Co-crystal............................................................................. 280

Cobalt ferrite nanoparticle.................................................... 169

Colistin.................................................................................... 13

Comet assay.......................................................................... 185

Cost saving........................................................................... 304

Croscarmellose sodium.......................................................... 40

CYP....................................................................................... 319

Cytotoxic activity................................................................... 290

Cytotoxicity.............................................................. 201,222,231

Desloratadine....................................................................... 148

Dexketoprofen trometamol........................................................ 1

Diclofenac sodium............................................................... 1,56

Dirithromycin....................................................................... 191

Disintegration......................................................................... 40

Dissolution................................................................ 40,120,280

DNA damage.......................................................... 169,185,257

Donepezil.............................................................................. 164

DPPH................................................................................... 179

Drug delivery..................................................................... 34,56

Drug pricing......................................................................... 264

Drug waste........................................................................... 304

EDCF.................................................................................... 207

Endemic................................................................................ 134

Endometrial cancer............................................................... 141

Endothelium.......................................................................... 207

Enzyme activation................................................................. 164

Epidermal growth factor receptor kinase............................. 285

EROD activity....................................................................... 174

Ethics.................................................................................... 264

Eudragit® RS100................................................................... 148

Eugenol................................................................................. 201

Extended-release tablets........................................................ 213

First-derivative synchronous spectrofluorimetry.................. 251

Free radical scavenging activity............................................ 179

Genotoxicity.......................................................................... 201

GSTM1................................................................................. 237

GSTT1.................................................................................. 237

Gynecologic cancers............................................................. 324

Health effects......................................................................... 311

Health policies...................................................................... 264

HeLa....................................................................................... 29

Herbicide.............................................................................. 185

High performance liquid chromatography........................... 179

Histopathology................................................................. 65,243

HPLC.................................................................................... 148

Human CAI........................................................................... 164

Human CAII......................................................................... 164

Imidazo[2,1-b]thiazole......................................................... 157

In vivo bioavailability study................................................... 120

IND......................................................................................... 84

Indion 414............................................................................... 40

Indomethacin........................................................................ 108

Inflammation............................................................. 19,274,324

Inhibition................................................................................... 9

Inhibitory.............................................................................. 285

Inos....................................................................................... 231

Insecticidal activity................................................................ 290

Interleukin 6............................................................................ 19

Internal and external predictability....................................... 120

Ischemia reperfusion injury.................................................. 257

IVIVC.................................................................................... 120

Kollidon® SR......................................................................... 191

Lead.......................................................................................... 9

Leaf and stem anatomy......................................................... 134          

Leguminosae......................................................................... 134

Lipid peroxidation................................................................. 174

Lipoxygenase.......................................................................... 49

Lung cancer.......................................................................... 319

Lycopene............................................................................... 311

Mass spectrometer................................................................ 294

MDA..................................................................................... 179

Medicinal plants.................................................................... 222

Melatonin................................................................................ 75

Memantine............................................................................ 164

Microspheres........................................................................ 243

Molecular docking.................................................................. 34

MTT................................................................................. 95,231

Nanoparticle......................................................................... 148

Naproxen sodium.................................................................. 120

Naringenin................................................................................ 9

Neuro-fuzzy logic.................................................................. 213

Neutral red.............................................................................. 95

NF-kb.................................................................................... 231

NKX3.1................................................................................. 274

Non-small cell lung carcinoma............................................. 237

NSAID................................................................................... 274

Ocular drug delivery............................................................. 191

Ononis.................................................................................. 134

Origanum acutidens............................................................... 29

Ovarian cancer..................................................................... 141

Oxazolidinones..................................................................... 174

Paroxetine hydrochloride...................................................... 251

Pathway................................................................................ 324

Patient rights......................................................................... 264

Pendimethalin....................................................................... 185

Pharmaceutical industry....................................................... 264

Pharmacists.......................................................................... 264

Pharmacoeconomy............................................................... 304

Pharmacological activity....................................................... 201

Phase 0................................................................................... 84

Phytoconstituents.................................................................. 324

Phytomelatonin....................................................................... 75

Phytotoxic activity.................................................................. 290

Pistacia atlantica..................................................................... 65

Plant phenolics........................................................................ 95

PLGA...................................................................................... 56

Poloxamers............................................................................. 56

Poly(e-caprolactone)............................................................... 56

Polymeric nanoparticles....................................................... 191

Polymorphism................................................................ 237,319

Preclinical testing.................................................................... 84

Prostate cancer..................................................................... 274

Protein expression................................................................ 237

Pseudo ternary phase diagram............................................. 108

Pycnogenol............................................................................ 257

Quality by design.................................................................. 213

Quercetin.............................................................................. 280

Quetiapine fumarate............................................................. 213

Radical scavenging................................................................. 29

Rat......................................................................................... 127

Response to chemotherapy.................................................... 319

Rho-kinaz.............................................................................. 207

Salicylic acid............................................................................. 1

Scorzonera latifolia............................................................... 179

sE-cadherin........................................................................... 141

Secondary metabolites.......................................................... 324

Self emulsifying drug delivery system.................................... 108

Skeletal muscle........................................................................ 19

Skin......................................................................................... 65

Skin reaction......................................................................... 127

Sodium starch glycolate.......................................................... 40

Solvent evaporation............................................................... 280

Statistical assessment............................................................ 294

Subcutaneous route............................................................... 127

Substance abuse.................................................................... 294

Succinic acid......................................................................... 280

Survival................................................................................. 319

Sustained release.................................................................. 120

Synthesis............................................................................... 174

Tanacetum argenteum subsp. argenteum............................. 231

TGF-b1................................................................................. 141

Thermosensitive hydrogel....................................................... 56

Tigecycline.............................................................................. 13

Time-kill.................................................................................. 13

Toxicity........................................................................... 127,201

Turkey................................................................................... 134

UPLC........................................................................................ 1

Urine..................................................................................... 294

Vaccine delivery.................................................................... 243

Validation.................................................................................. 1

Vitronectin............................................................................. 141

Wet granulation.................................................................... 213

Wetting.................................................................................... 40

Wound healing........................................................................ 65

Zeta potential ....................................................................... 108